Aktuality vo vede

V tejto sekcii nájdete výber článkov zo svetovej odbornej literatúry.


Účinnosť a bezpečnosť kombinovanej terapie GLP-1 RA spolu s inhibítormi SGLT-2 u DM 2. typu: Systematický prehľad a metaanalýza

Autori:  Chen Li 1,2, Jie Luo 1,2, Mingyan Jiang 1,2 and Wang1,2, 1Department of Pharmacy, The First Hospital of China Medical University, Shenyang, China, 2School of Pharmacy, China Medical University, Shenyang, China
pridal plasil.r_1668 dňa 2. jún 2022 - 19:29

New ESC guideline recommends SGLT2 inhibitors for HFrEF

Autori:  McDonagh TA, et al. Eur Heart J. 2021;doi:10.1093/eurheartj/ehab368. Zdroj:  European Journal of Heart Failure
pridal plasil.r_1668 dňa 12. december 2021 - 10:43

Dapagliflozin in Patients with Chronic Kidney Disease

Autori:  Hiddo J.L. Heerspink, Ph.D., Bergur V. Stefánsson, M.D., Ricardo Correa-Rotter, M.D., Glenn M. Chertow, M.D., Tom Greene, Ph.D., Fan-Fan Hou, M.D., Johannes F.E. Mann, M.D., John J.V. McMurray, M.D., Magnus Lindberg, M.Sc., Peter Rossing, M.D., C. David Sjöström, M.D., Roberto D. Toto, M.D., et al., for the DAPA-CKD Trial Committees and Investigators* Zdroj:  The NEW ENGLAND JOURNAL of MEDICINE
pridal plasil.r_1668 dňa 12. december 2021 - 10:30

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Autori:  Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén, Denis Xavier, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Purnima Rao-Melacini, Gloria Wong, Alvaro Avezum, Jan Basile, Namsik Chung, Ignacio Conget, William C Cushman, Edward Franek, Nicolae Hancu, Markolf Hanefeld, Shaun Holt, Petr Jansky, Matyas Keltai, Fernando Lanas, Lawrence A Leiter, Patricio Lopez-Jaramillo, Ernesto German Cardona Munoz, Valdis Pirags, Nana Pogosova, Peter J Raubenheimer, Jonathan E Shaw, Wayne H-H Sheu, Theodora Temelkova-Kurktschiev, for the REWIND Investigators* Zdroj:  The Lancet
pridal plasil.r_1668 dňa 22. október 2021 - 11:58

Incretin-based therapies in 2021 – Current status and perspectives for the future

Autori:  Manfredi Rizzo (a,b), Michael A. Nauck (c) and Christos S. Mantzorosd (d,e) Metabolism. 2021 Sep; 122: 154843. Published online 2021 Jul 30. doi: 10.1016/j.metabol.2021.154843 PMCID: PMC8321622 PMID: 34333000 I
pridal plasil.r_1668 dňa 17. august 2021 - 15:23

Standards of Medical Care in Diabetes—2021 Abridged for Primary Care Providers American Diabetes Association

Autori:  American Diabetes Association Clinical Diabetes 2021 Jan; 39(1): 14-43. https://doi.org/10.2337/cd21-as01 Zdroj:  American Diabetes Association
pridal plasil.r_1668 dňa 6. jún 2021 - 17:29

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Autori:  Fernando P. Polack, M.D., Stephen J. Thomas, M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., John L. Perez, M.D., Gonzalo Pérez Marc, M.D., Edson D. Moreira, M.D., Cristiano Zerbini, M.D., Ruth Bailey, B.Sc., Kena A. Swanson, Ph.D., et al., for the C4591001 Clinical Trial Group* Zdroj:  The NEW ENGLAND JOURNAL of MEDICINE
pridal plasil.r_1668 dňa 18. január 2021 - 12:07

Expert Opinion on the Therapeutic Use of the FixedRatio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective

Autori:  M. Haluzík, M. Flekač, C. Lengyel, Z. Taybani, C. Guja, B.M. Mihai, A. Cerghizan, E. Martinka, G Kovacs, P. Kempler, Diabetes Ther https://doi.org/10.1007/s13300-020-00777-2, Received: December 23, 2019, The Author(s) 2020
pridal plasil.r_1668 dňa 8. december 2020 - 15:48

Deintenzifikace na fixní směs inzulinu glargin a lixisenatidu jako cesta k moderní antidiabetické terapii osob s diabetes mellitus 2. typu

Autori:  M. Flekač, III. interní klinika VFN a 1. LF UK, Praha
pridal plasil.r_1668 dňa 8. december 2020 - 15:42

Stránky